CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing markets

Strategic transformation driven by a comprehensive data analysis will enable new executive team to leverage decades of experience in these therapeutic areas

Company pivoting from a singular focus on glioblastoma and will explore out-licensing of legacy assets berubicin and TPI 287

HOUSTON, TX / ACCESS Newswire / March 11, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (the "Company"), a biotechnology company focused on building a pipeline of innovative therapies in high-value neurology and oncology markets, today announced that it has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive team with deep experience across neurology, oncology and rare disease drug development. The team is driving a disciplined, data-driven approach to identify, acquire and advance differentiated therapeutic programs capable of delivering meaningful clinical and commercial value.

CNS Pharmaceuticals conducted an independent, rigorous evaluation of its existing pipeline, development priorities and broader market opportunities as part of a comprehensive strategic review. The process incorporated clinical probability-of-success modeling, competitive landscape assessments, regulatory pathway evaluations and risk-adjusted return analyses. The review was carried out in collaboration with external strategic advisors to ensure a disciplined, scientifically grounded and commercially focused path forward.

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, commented, "We have made impactful progress in a very short period of time and are expecting 2026 to be a year of transformation and execution for CNS Pharmaceuticals. In parallel to a hand-picked, newly formed executive team, we immediately engaged a preeminent consulting firm and have now completed a robust and highly analytical review of our pipeline, development priorities and long-term positioning. We believe CNS Pharmaceuticals is uniquely positioned to leverage the deep expertise of our leadership team and a disciplined approach to capital allocation to build a next-generation biotechnology company focused on high-value opportunities in neurology and oncology."